BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kägi G, Raw J, Stefani A, Warnecke T, Jost WH; SYNAPSES Study Investigators Group. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. J Parkinsons Dis 2021;11:187-98. [PMID: 33104040 DOI: 10.3233/JPD-202224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Hattori N, Kamei T, Ishida T, Suzuki I, Nomoto M, Tsuboi Y. Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study. J Neural Transm (Vienna) 2022. [PMID: 36001147 DOI: 10.1007/s00702-022-02532-2] [Reference Citation Analysis]
2 Ronconi G, Calabria S, Piccinni C, Dondi L, Pedrini A, Esposito I, Addesi A, Sambati L, Martini N. Prescription Pattern of Monoamine Oxidase B Inhibitors Combined with Levodopa: A Retrospective Observational Analysis of Italian Healthcare Administrative Databases. Drugs Real World Outcomes 2022. [PMID: 35696024 DOI: 10.1007/s40801-022-00308-4] [Reference Citation Analysis]
3 Kulisevsky J, Martínez-horta S, Campolongo A, Pascual-sedano B, Marín-lahoz J, Bejr-kasem H, Aracil-bolaños I, Horta-barba A, Puig-davi A, Pagonabarraga J. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease. Front Neurol 2022;13:866502. [DOI: 10.3389/fneur.2022.866502] [Reference Citation Analysis]
4 Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J Parkinsons Dis 2022;12:477-93. [PMID: 34957948 DOI: 10.3233/JPD-212976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Stocchi F, Antonini A, Berg D, Bergmans B, Jost W, Katzenschlager R, Kulisevsky J, Odin P, Valldeoriola F, Ray Chaudhuri K. Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. NPJ Parkinsons Dis 2022;8:17. [PMID: 35190544 DOI: 10.1038/s41531-022-00277-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jost WH. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. J Neural Transm (Vienna) 2022. [PMID: 35107654 DOI: 10.1007/s00702-022-02465-w] [Reference Citation Analysis]
7 Pellecchia MT, Picillo M, Russillo MC, De Pandis MF, Bonizzoni E, Marjanovic I, Cattaneo C. Efficacy of Safinamide and Gender Differences During Routine Clinical Practice. Front Neurol 2021;12:756304. [PMID: 34970207 DOI: 10.3389/fneur.2021.756304] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Kurihara K, Mishima T, Fujioka S, Tsuboi Y. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease. Expert Opin Drug Saf 2021;:1-11. [PMID: 34597253 DOI: 10.1080/14740338.2022.1988926] [Reference Citation Analysis]
9 Mylius V, Möller JC, Bohlhalter S, Ciampi de Andrade D, Perez Lloret S. Diagnosis and Management of Pain in Parkinson's Disease: A New Approach. Drugs Aging 2021;38:559-77. [PMID: 34224103 DOI: 10.1007/s40266-021-00867-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Fernandes M, Pierantozzi M, Stefani A, Cattaneo C, Bonizzoni EA, Cerroni R, Mercuri NB, Liguori C. Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. Front Neurol 2021;12:678373. [PMID: 34267721 DOI: 10.3389/fneur.2021.678373] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Santos García D, Labandeira Guerra C, Yáñez Baña R, Cimas Hernando MI, Cabo López I, Paz Gonález JM, Alonso Losada MG, González Palmás MJ, Martínez Miró C. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study. Brain Sci 2021;11:316. [PMID: 33801565 DOI: 10.3390/brainsci11030316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
12 Peña E, Borrué C, Mata M, Martínez-Castrillo JC, Alonso-Canovas A, Chico JL, López-Manzanares L, Llanero M, Herreros-Rodríguez J, Esquivel A, Maycas-Cepeda T, Ruíz-Huete C. Impact of SAfinamide on Depressive Symptoms in Parkinson's Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Brain Sci 2021;11:232. [PMID: 33668408 DOI: 10.3390/brainsci11020232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]